The Shotlee Journal
Browse Shotlee articles about Metabolic Health.
Showing 9 / 741 Metabolic Health articles
The FDA has issued a critical warning regarding counterfeit tirzepatide products. Discover the risks of fake GLP-1 medications and how to verify legitimate sources for your weight loss journey.
Dr. Stacy Smalley shares her transformative journey of losing 94 pounds by eliminating sugar, detailing how it silenced persistent cravings and improved her overall well-being. This article explores the science behind sugar's impact on appetite and provides actionable strategies for readers to achieve similar results.
Emerging research from Ben-Gurion University suggests Semaglutide and Colchicine may prevent atrial fibrillation by reducing inflammation and cardiac scarring.
The Canadian market sees the arrival of a generic semaglutide injection, a significant development for individuals managing type 2 diabetes and seeking weight loss solutions. This launch by Dr. Reddy's Laboratories marks a new era of accessibility for this popular GLP-1 therapy.
GLP-1 medications like Ozempic and Wegovy are transforming weight management, but understanding your body's response is key. Learn how innovative health monitors can help you track progress and manage side effects effectively.
Researchers at UC Riverside have uncovered promising data linking cannabis oil to improved metabolic function and weight loss in mice, sparking debate about its potential as a future therapy alongside GLP-1 medications.
The popularity of GLP-1 receptor agonists for weight management is soaring. This article delves into the latest trends, the science behind these medications, and essential considerations for patients and healthcare providers.
This comprehensive update delves into groundbreaking research on GLP-1 receptor agonists and their impact on liver health, alongside crucial developments in inflammatory bowel disease (IBD) management and innovative approaches to digestive symptom relief. Discover how cutting-edge science is shaping patient care and explore practical implications for managing chronic conditions.
New Zealand's Pharmac funding agency has moved semaglutide (Wegovy) to its investment list. Here is what this means for eligibility, costs, and access.
